Yasser Bustanji

Prof. Yasser Bustanji

University of Sharjah, Sharjah, Ash Shāriqah, United Arab Emirates
+1
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Nutrition Research
Verified
Journal Article
Closed access
MoezAlIslam Ezzat FarisMoezAlIslam Ezzat Faris
MoezAlIslam Ezzat Faris
SKSafia Kacimi
Safia Kacimi
RARef'At A. Al-Kurd
Ref'At A. Al-Kurd
MFMohammad A. Fararjeh
Mohammad A. Fararjeh
YBYasser Bustanji
Yasser Bustanji
MSMohammad L. Salem
Mohammad L. Salem

1 October 2008 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MHMohammad Hudaib
Mohammad Hudaib
MMMohammad Mohammad
Mohammad Mohammad
YBYasser Bustanji
Yasser Bustanji
RTRabab Tayyem
Rabab Tayyem
MYMohammed Yousef
Mohammed Yousef
TATalal Ahmad Aburjai
Talal Ahmad Aburjai

12 June 2007 in Pharmacy World & Science
Verified
Journal Article
Closed access
PDF file
AYAl-Motassem Yousef
Al-Motassem Yousef
AAAmal G. Al-Bakri
Amal G. Al-Bakri
YBYasser Bustanji
Yasser Bustanji
MWMayyada Wazaify
Mayyada Wazaify

1 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RQReem A. Qannita
Reem A. Qannita
AAAyah I. Alalami
Ayah I. Alalami
Amani A. HarbAmani A. Harb
Amani A. Harb
Shereen M. AleidiShereen M. Aleidi
Shereen M. Aleidi
JTJalal Taneera
Jalal Taneera
YBYasser Bustanji
Yasser Bustanji
Hypoxia-inducible factor-1 (HIF-1) is a key regulator for balancing oxygen in the cells. It is a transcription factor that regulates the expression of target genes involved in oxygen homeostasis in response to hypoxia. Recently, research has demonstrated the multiple roles of HIF-1 in the pathophysiology of various diseases, including cancer. It is a crucial mediator of the hypoxic response and regulator of oxygen metabolism, thus contributing to tumor development and progression. Studies showed that the expression of the HIF-1α subunit is significantly upregulated in cancer cells and promotes tumor survival by multiple mechanisms. In addition, HIF-1 has potential contributing roles in cancer progression, including cell division, survival, proliferation, angiogenesis, and metastasis. Moreover, HIF-1 has a role in regulating cellular metabolic pathways, particularly the anaerobic metabolism of glucose. Given its significant and potential roles in cancer development and progression, it has been an intriguing therapeutic target for cancer research. Several compounds targeting HIF-1-associated processes are now being used to treat different types of cancer. This review outlines emerging therapeutic strategies that target HIF-1 as well as the relevance and regulation of the HIF-1 pathways in cancer. Moreover, it addresses the employment of nanotechnology in developing these promising strategies.

28 October 2010 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
YBYasser Bustanji
Yasser Bustanji
IAIhab M. Al-Masri
Ihab M. Al-Masri
MMMohammad Mohammad
Mohammad Mohammad
MHMohammad Hudaib
Mohammad Hudaib
KTKhaled Tawaha
Khaled Tawaha
HAHatim S AlKhatib
Hatim S AlKhatib
The prevalence of obesity is increasing at an alarming rate, but, unfortunately, only a few drugs are currently available on the market. In the present study, the methanolic extract of Ginkgo biloba L. (Ginkgoaceae) was investigated as an inhibitor of pancreatic lipase (PL) in an attempt to explain its hypolipidaemic activity. In vitro assay of G. biloba leaves extract revealed a substantial PL inhibition activity (IC50 = 16.5 µg/mL). Further investigation was performed by employing theoretical docking simulations and experimental testing to uncover the active constituents responsible for G. biloba anti-lipase activity. Virtually, terpene trilactones, including ginkgolides and bilobalide, were found to fit within the binding pocket of PL via several attractive interactions with key amino acids. Experimentally, ginkgolides A, B, and bilobalide were found to inhibit PL significantly (IC50 = 22.9, 90.0, and 60.1 µg/mL, respectively). Our findings demonstrated that the hypolipidaemic effects of G. biloba extract can be attributed to the inhibition of PL by, at least in part, terpene trilactones. In conclusion, this work can be considered a new step towards the discovery of new natural safe hypolipidaemic PL inhibitors.

5 June 2009 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
AAAmal G. Al-Bakri
Amal G. Al-Bakri
GOG. Othman
G. Othman
YBYasser Bustanji
Yasser Bustanji
Aims: To evaluate the antimicrobial activities of aspirin, EDTA and an aspirin-EDTA (A-EDTA) combination against Pseudomonas aeruginosa, Escherichia coli and Candida albicans in planktonic and biofilm cultures. Methods and Results: Minimal inhibitory concentrations (MIC) and minimal biocidal concentrations (MBC) were determined using twofold broth microdilution and viable counting methods, respectively. Aspirin’s recorded MIC values ranged from 1·2 to 2·7 mg ml−1. Checkerboard assay demonstrated a synergism in antimicrobial activity upon combination. Aspirin’s minimal biofilm eradication concentration values (MBEC) against the established biofilms ranged between 1·35 and 3·83 mg ml−1. A complete eradication of bacterial biofilms was achieved after a 4-h treatment with the A-EDTA combination. Conclusion: Both aspirin and EDTA possess broad-spectrum antimicrobial activity for both planktonic and biofilm cultures. Aspirin used at the MBEC for 24 h was successful in eradicating P. aeruginosa, E. coli and C. albicans biofilms established on abiotic surfaces. Moreover, the exposure to the A-EDTA combination (4 h) effected complete bacterial biofilm eradication. Significance and Impact of the Study: There is a continuous need for the discovery of new antimicrobial agents. Aspirin and EDTA are ‘nonantibiotic drugs’, the combination of which can be used successfully to treat and eradicate biofilms established on abiotic surfaces.